Spots Global Cancer Trial Database for Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
Official Title: An Open Label, Multicenter Study of First-Line Durvalumab Plus Platinum-Based Chemotherapy in Chinese Patients With Extensive Stage Small-Cell Lung Cancer (Oriental)
Study ID: NCT04449861
Interventions
Study Description
Brief Summary: This will be an open-label, single-arm, multicenter, Phase IIIb study to determine the safety of durvalumab + etoposide and cisplatin or carboplatin as first-line treatment in patients with extensive stage small-cell lung cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Baoding, , China
Research Site, Changchun, , China
Research Site, Chengdu, , China
Research Site, Dalian, , China
Research Site, Dongyang, , China
Research Site, Guangdong, , China
Research Site, Guangzhou, , China
Research Site, Guangzhou, , China
Research Site, Haerbin, , China
Research Site, Hangzhou, , China
Research Site, Hangzhou, , China
Research Site, Hefei, , China
Research Site, Huai'an, , China
Research Site, Jiangyin, , China
Research Site, Jinan, , China
Research Site, Jinhua, , China
Research Site, Nanchang, , China
Research Site, Nanjing, , China
Research Site, Ningbo, , China
Research Site, Qingdao, , China
Research Site, Shanghai, , China
Research Site, Shanghai, , China
Research Site, ShenZhen, , China
Research Site, Taizhou, , China
Research Site, Tianjin, , China
Research Site, Whenzhou, , China
Research Site, Wuhan, , China
Research Site, Wuxi, , China
Research Site, Yangzhou, , China
Research Site, Zhengzhou, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
